|
1
|
Sundar R, Nakayama I, Markar SR, Shitara
K, van Laarhoven HWM, Janjigian YY and Smyth EC: Gastric cancer.
Lancet. 405:2087–2102. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang X, Zhang J, Ma J, Huang J, Wang Y,
Wang P, Wang F and Tang X: GPER governs the immune infiltration of
gastric cancer and activates the NF-κB/ROS/Apoptosis pathway in
gastric mucosal epithelium. Int Immunopharmacol. 122:1106412023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
4
|
Lordick F, Carneiro F, Cascinu S, Fleitas
T, Haustermans K, Piessen G, Vogel A and Smyth EC; ESMO Guidelines
Committee. Electronic address, : simpleclinicalguidelines@esmo.org:
Gastric cancer: ESMO clinical practice guideline for diagnosis,
treatment and follow-up. Ann Oncol. 33:1005–1020. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao L, Huang H, Zhang C, Luan X, Niu P,
Zhu Y, Xiong Y, Wang W, Han X, Huang D, et al: Temporospatial
variation in environmental risk factors and related gastric cancer
incidence: A registry-based study in an area with the largest
gastric cancer burden in China. J Glob Health. 15:040832025.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou L, Han B, Yuan Y, Dong Z, Shi Y and
Zheng R: The global burden of stomach cancer and its risk factors
from 1990 to 2021: Findings from the global burden of disease study
2021. BMC Public Health. 25:26782025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Petrillo A and Smyth EC: Biomarkers for
precision treatment in gastric cancer. Visc Med. 36:364–372. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao YX, Guo XJ, Lin B, Huang XB, Tu RH,
Lin M, Cao LL, Chen QY, Wang JB, Xie JW, et al: Targeting LHPP in
neoadjuvant chemotherapy resistance of gastric cancer: Insights
from single-cell and multi-omics data on tumor immune
microenvironment and stemness characteristics. Cell Death Dis.
16:3062025. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou J, Li J, Chen J, Lan X, Ai Y, Liu P,
Peng J, Pan X, Zhang Y, Zhang H, et al: Decoding inflammatory
mediators in the Correa's cascade: From chronic gastritis to
carcinogenesis and targeted therapies. Int Immunopharmacol.
162:1151912025. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi Y, Jia E, Wu X and Wang F:
Upregulation of MFAP5 enhances COL1A1 expression, promoting
epithelial-mesenchymal transition in gastric cancer cells. Discov
Med. 36:2079–2087. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Coorens THH, Collord G, Jung H, Wang Y,
Moore L, Hooks Y, Mahbubani K, Law SYK, Yan HHN, Yuen ST, et al:
The somatic mutation landscape of normal gastric epithelium.
Nature. 640:418–426. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu B, Liu H, Ren F, Liu H, Bukhari I, Fu
Y, Wu W, Zhao M, Zhu S, Mo H, et al: cGAS regulates the DNA damage
response to maintain proliferative signaling in gastric cancer
cells. Oncol Res. 29:87–103. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu H, Yang H, Fan S, Jia X, Zhao Y and Li
H: LncRNA HOTAIR promotes DNA damage repair and radioresistance by
targeting ATR in colorectal cancer. Oncol Res. 32:1335–1346. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaiser L, Ondrus M, Slavetinska LP,
Raindlova V and Hocek M: Polymerase synthesis of hypermodified DNA
displaying a combination of thiol, hydroxyl, carboxylate, and
imidazole functional groups in the major groove. Chemistry.
31:e2025010342025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garzon J, Rodriguez R, Kong Z, Chabes A,
Rodriguez-Acebes S, Mendez J, Moreno S and García-Higuera I:
Shortage of dNTPs underlies altered replication dynamics and DNA
breakage in the absence of the APC/C cofactor Cdh1. Oncogene.
36:5808–5818. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Long MJC, Van Hall-Beauvais A and Aye Y:
The more the merrier: How homo-oligomerization alters the
interactome and function of ribonucleotide reductase. Curr Opin
Chem Biol. 54:10–18. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo L, Zhao Y, Bai X, Wang X, Tuoheti K,
Cao Y, Zuo Y, Zhang X and Liu T: RRM2 is a putative biomarker and
promotes bladder cancer progression via PI3K/AKT/mTOR pathway. J
Cell Physiol. 240:e315012025. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu K, Wang L, Lou Z, Guo L, Xu Y, Qi H,
Fang Z, Mei L, Chen X, Zhang X, et al: E2F8 exerts cancer-promoting
effects by transcriptionally activating RRM2 and E2F8 knockdown
synergizes with WEE1 inhibition in suppressing lung adenocarcinoma.
Biochem Pharmacol. 218:1158542023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mao G, Li L, Shan C, Liang B, Ma L and
Zhang S: High expression of RRM2 mediated by non-coding RNAs
correlates with poor prognosis and tumor immune infiltration of
hepatocellular carcinoma. Front Med (Lausanne). 9:8333012022.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shi SC, Zhang Y and Wang T: High RRM2
expression has poor prognosis in specific types of breast cancer.
PLoS One. 17:e02651952022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abdel-Rahman MA, Mahfouz M and Habashy HO:
RRM2 expression in different molecular subtypes of breast cancer
and its prognostic significance. Diagn Pathol. 17:12022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE,
Park KC, Lee SH, Park JL, Park YY, Lee HS, et al: Clinical and
genomic landscape of gastric cancer with a mesenchymal phenotype.
Nat Commun. 9:17772018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheong JH, Yang HK, Kim H, Kim WH, Kim YW,
Kook MC, Park YK, Kim HH, Lee HS, Lee KH, et al: Predictive test
for chemotherapy response in resectable gastric cancer: A
multi-cohort, retrospective analysis. Lancet Oncol. 19:629–638.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang H, Yu D, Yang P, Guo R, Kong M, Gao
Y, Yu X, Lu X and Fan X: Revealing the transcriptional
heterogeneity of organ-specific metastasis in human gastric cancer
using single-cell RNA Sequencing. Clin Transl Med. 12:e7302022.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhan Y, Jiang L, Jin X, Ying S, Wu Z, Wang
L, Yu W, Tong J, Zhang L, Lou Y and Qiu Y: Inhibiting RRM2 to
enhance the anticancer activity of chemotherapy. Biomed
Pharmacother. 133:1109962021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zuo Z, Zhou Z, Chang Y, Liu Y, Shen Y, Li
Q and Zhang L: Ribonucleotide reductase M2 (RRM2): Regulation,
function and targeting strategy in human cancer. Genes Dis.
11:218–233. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang XJ, Huo YX, Yang PJ, Gao J and Hu WD:
Significance of ribonucleoside-diphosphate reductase subunit M2 in
lung adenocarcinoma. Curr Gene Ther. 25:136–156. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han P, Chen RH, Wang F, Zeng JY, Yu ST, Xu
LH, Cai Q, Liang FY, Xia TL, Lin ZR, et al: Novel chimeric
transcript RRM2-c2orf48 promotes metastasis in nasopharyngeal
carcinoma. Cell Death Dis. 8:e30472017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu Q, Song C, Li J, Liu M, Fu L, Jiang J,
Zeng Z and Zhu H: E2F2 enhances the chemoresistance of pancreatic
cancer to gemcitabine by regulating the cell cycle and upregulating
the expression of RRM2. Med Oncol. 39:1242022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Perrault EN, Shireman JM, Ali ES, Lin P,
Preddy I, Park C, Budhiraja S, Baisiwala S, Dixit K, James CD, et
al: Ribonucleotide reductase regulatory subunit M2 drives
glioblastoma TMZ resistance through modulation of dNTP production.
Sci Adv. 9:eade72362023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma C, Luo H, Cao J, Gao C, Fa X and Wang
G: Independent prognostic implications of RRM2 in lung
adenocarcinoma. J Cancer. 11:7009–7022. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang J, Yi Y, Chen Y, Xiong Y and Zhang W:
Potential mechanism of RRM2 for promoting cervical cancer based on
weighted gene co-expression network analysis. Int J Med Sci.
17:2362–2372. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng B, Li L, Wu Y, Luo T, Tang C, Wang
Q, Zhou Q, Wu J, Lai Y, Zhu D, et al: The key cellular senescence
related molecule RRM2 regulates prostate cancer progression and
resistance to docetaxel treatment. Cell Biosci. 13:2112023.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou Z, Song Q, Yang Y, Wang L and Wu Z:
Comprehensive landscape of RRM2 with immune infiltration in
pan-cancer. Cancers (Basel). 14:29382022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee SK, Hwang Y, Han JH, Haam S, Lee HW
and Koh YW: Characteristics of the immune microenvironment
associated with RRM2 expression and its application to PD-L1/PD-1
inhibitors in lung adenocarcinoma. Am J Cancer Res. 13:5443–5454.
2023.PubMed/NCBI
|
|
37
|
Wu L, Yin L, Ma L, Yang J, Yang F, Sun B
and Nianzeng X: Comprehensive bioinformatics analysis of
ribonucleoside diphosphate reductase subunit M2(RRM2) gene
correlates with prognosis and tumor immunotherapy in pan-cancer.
Aging (Albany NY). 14:7890–7905. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang Y, Chen R, Zhang J and Zeng P: A
comprehensive analysis of ribonucleotide reductase subunit M2 for
carcinogenesis in pan-cancer. PLoS One. 19:e02999492024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tan J, Wang W, Liu X, Xu J, Che Y, Liu Y,
Hu J, Hu L, Li J and Zhou Q: C11orf54 promotes DNA repair via
blocking CMA-mediated degradation of HIF1A. Commun Biol. 6:6062023.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Morikawa T, Hino R, Uozaki H, Maeda D,
Ushiku T, Shinozaki A, Sakatani T and Fukayama M: Expression of
ribonucleotide reductase M2 subunit in gastric cancer and effects
of RRM2 inhibition in vitro. Hum Pathol. 41:1742–1748. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ping S, Jia X and Tian Y: Integration of
scRNA-seq and ST-seq identifies hyperproliferative RRM2+ cells
features and therapeutic targets in gastric cancer. J Transl Med.
23:7952025. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sun X, Duan K, Shen X, Dong C, Zhou Y,
Chen T, Li W, Li P, Wang P, Li D and Zhou J: Construction and
validation of a nomogram model for predicting peritoneal metastasis
in gastric cancer based on ferroptosis-relate genes and
clinicopathological features. J Gastrointest Oncol. 16:264–280.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Giang LH, Wu KS, Lee WC, Chu SS, Do AD,
Huang MH, Lin YL, Hsieh CL, Sung SY, Yen Y, et al: RRM2 inhibition
alters cell cycle through ATM/Rb/E2F1 pathway in atypical teratoid
rhabdoid tumor. Neoplasia. 58:1010752024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Luo XJ, Lu YX, Wang Y, Huang R, Liu J, Jin
Y, Liu ZK, Liu ZX, Huang QT, Pu HY, et al: M6A-modified lncRNA
FAM83H-AS1 promotes colorectal cancer progression through PTBP1.
Cancer Lett. 598:2170852024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vriend LE, Jasin M and Krawczyk PM:
Assaying break and nick-induced homologous recombination in
mammalian cells using the DR-GFP reporter and Cas9 nucleases.
Methods Enzymol. 546:175–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang N, Tian YN, Zhou LN, Li MZ, Chen HD,
Song SS, Huan XJ, Bao XB, Zhang A, Miao ZH and He JX: Glycogen
synthase kinase 3beta inhibition synergizes with PARP inhibitors
through the induction of homologous recombination deficiency in
colorectal cancer. Cell Death Dis. 12:1832021. View Article : Google Scholar : PubMed/NCBI
|
